Share on LinkedInShare on LinkedIn

ARTICLE · 24 SEPTEMBER 2006

The Global Lipitor Patent Scorecard (as at 21 September 2006)

The following scorecard was included in two recent articles. Due to popular demand, I will separately keep it up to date as new results occur.

GlobalIntellectual Property

Background

The following scorecard was included in two recent articles. Due to popular demand, I will separately keep it up to date as new results occur. Feedback and further news is, as always, very welcome.

Since the last update, Ranbaxy has received non-infringement findings in Norway and invalidated the Enantiomer patent in the Netherlands. However, Pfizer’s patent monopoly will stand in each of these two countries until 2009 and 2011 respectively.

My two most recent articles were:

  • BP green colour mark revoked by Australian Full Court
  • US Court of Appeal invalidates Lipitor patent due to improper claim dependency
  • The scorecard

    Country

    Date

    Comment

    Austria

    Apr 06

    We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

    See more popular content from